UNSPSC 51142541: Amantadine sulfate

This classification denotes a miscellaneous antiviral agent and cation channel blocker with the molecular formula 2C10H17N.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9921T5P019. European Medicines Agency schedules amantadine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00423MIG. The term amantadine sulfate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule amantadine sulfate under HS 29213099 and SITC 51453.

As of Q4 2014, AMANTADINE SULFATE remains US FDA's Preferred Term for this commodity. Amantadine sulfate bears US NLM identifiers UMLS ID C0002404 and NCI Concept Code C90781. SMILES: C1C2CC3CC1CC(C2)(C3)N.OS(=O)(=O)O.

UNSPSC 51142541 Amantadine sulfate is a Commodity code that in practice captures state and local procurement of pharmaceutical products, including both generic multi-source pharmaceuticals and specialized medications like naloxone and drug deactivation systems for public health initiatives. The code appears in recent solicitations driven by health departments, county health agencies, and multistate cooperative purchasing vehicles acquiring inventory for community health programs, emergency response, and pharmacy benefit management. Work under this code ranges from direct annual purchases of specific therapeutic agents to cooperative contracting frameworks that establish pricing and supply relationships with multiple authorized wholesalers serving state and local government facilities.

Recent activity shows issuers across at least Florida and Minnesota, with a multistate cooperative (MMCAP) administered by the Minnesota Department of Administration spanning participating state and local facilities including Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2023 and quarterly deliveries to the Seminole County Community Health Building; bidders must include all shipping and delivery costs and comply with E-Verify and drug-free workplace requirements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with products available by May 15, 2026, and the resulting contract effective July 1, 2026; evaluation weighted pricing competitiveness at 75 percent and required certification of current Good Manufacturing Practices and Drug Supply Chain Security Act compliance. The Texas Health and Human Services Commission issued an RFI (posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager and group purchasing organization channels, signaling upstream procurement strategy development for pharmacy benefit programs.